Retinopathy

Retinopathy (DR) is the most severe among these ocular complications . It is the most frequent cause of new cases of blindness among adults aged 20–74 years.  Diabetic retinopathy (DR) is the most common vascular complication in patients with long-standing diabetes, and is the leading cause of blindness in working-age adults. The estimated prevalence in USA is 5.4% (~7 million). Future projections suggest that DR will increase as a public health problem, with increase in aged population and increasing prevalence of diabetes over time.

A number of studies showed that stem cells have regenerative ability, not only by direct differentiation and incorporation into the vasculature but also via a paracrine manner on the residential cells, thereby promoting normal vascularization in animal OIR models. Stem cell therapy as a medical treatment has ushered in a new era.

Mesenchymal cells in particular Adipose stem cells (ASC) are preferred choices of cell therapy in ischemic and diabetic diseases. The ready availability of large numbers of autologous cells with the capabilities of facilitating repair of vascular and neurogenic tissues would be highly significant clinically for patients with retinal diseases such as AMD, DR, and retinitis pigmentosa.

The ability of MSCs to maintain and restore the neural retina damaged in degenerative diseases was demonstrated for age-related macular degeneration (AMD) and retinitis pigmentosa (RP). When injected locally or systemically, engrafted MSCs were reported to provide visual protection and a delay in degeneration

The resulting therapies would involve a minimally invasive procedure such as liposuction to harvest adipose tissue, followed by any processing required to obtain an appropriately defined and functionally consistent population of cells with the desired

The sources of our stem cells, bone marrow , adipose tissue (fat) and peripheral blood are from the patient’s own body which are processed in our ISO9001:2015 certified clinic and GLP certified laboratory using the latest and safest  methods.

Any of the three method of obtaining the cells will help in preventing neurovascular damage and promoting regeneration of damaged retina, as evidenced by recent studies with several types of stem cells.

Mesenchymal cells in particular ASC are preferred choices of cell therapy in ischemic and diabetic diseases. The ready availability of large numbers of autologous cells with the capabilities of facilitating repair of vascular and neurogenic tissues would be highly significant clinically for patients with retinal diseases such as AMD, DR, and retinitis pigmentosa.  http://journal.frontiersin.org/article/10.3389/fendo.2014.00059/full

It is important to be able to consistently produce high-quality stem cells for transplant into patients and World Stem Cell Clinic worldstemcellclinic.com with their past and present research and clinic treatments feel we have an autologous stem cells from bone marrow, adipose, peripheral blood or allogenic cells from amnion, cord blood, wj, plasma proteins therapy that can benefit patients with eye  diseases.

The Stem Cell Treatment at World Stem Cell Clinic https://worldstemcellclinic.com More important is no long-term negative side effects or risks have been reported.

Please fill in the “free Consultation” form and see if you qualify for a stem cell treatment today

• At World Stem Cell Clinic and The Royal British Medical Center we practice “Patient Precision Medicine (PPM)” which is a treatment model that proposes the customization of the treatment to each unique patient based on their medical history, stage of disease, exam results, time available for treatment and a patient orientation meeting with our Doctors before determining the best treatment for each unique patient.

• Our staff physicians are all board certified, in their field with years of experience. Your team includes both primary and ancillary care professionals devoted to maximizing your benefits from the procedures. We enroll you in an open registry to track your changes independently, for up to 5 years.

• To maintain our “Patient Precision Medicine (PPM)” services for you we may use peripheral blood, bone marrow, adipose or umbilical cord derived cells, plasma, proteins and Extracellular Vesicles based your unique treatment needs with mutual agreement.

• As our patient we also keep you abreast of the newest developments in treatment research. This is an ongoing relationship to maintain and enhance your health.

• Our promise is to provide you with travel and lodging support, access to bilingual staff members throughout the entire process and most importantly the best medical care possible.